2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gastrointestinal
1
Breast
1
Conditions
Solid Tumors
2
Neoplasms
2
Liposarcoma
2
Biliary Tract Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Solid Tumours
1
Sarcoma
1
Pancreatic Neoplasms
1
Lung Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Glioblastoma
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Fluorouracil
497
Bevacizumab
476
Oxaliplatin
449
Leucovorin
440
Irinotecan
408
Cetuximab
317
Capecitabine
317
pembrolizumab
142
Folfox protocol
129
Panitumumab
117
regorafenib
105
Colonoscopy
88
Nivolumab
81
IFL protocol
81
Drug Therapy
77
trifluridine tipiracil drug combination
73
Radiotherapy
66
HMPL-013
65
Blood Specimen Collection
52
Gemcitabine
49
Specimen Handling
46
Neoadjuvant Therapy
45
Standard of Care
44
Magnetic Resonance Spectroscopy
43
Biopsy
43
Chemotherapy, Adjuvant
41
Trifluridine
40
atezolizumab
38
Surveys and Questionnaires
38
Cyclophosphamide
38
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
brigimadlin
×
Clear all
NCT06084689
2025-09-02
EMPIRE
Institut Bergonié
Phase 2
Withdrawn